Table 3.

Summary of the coBRIM efficacy results along with the reported dermatologic adverse events^a.

Study group			Cobimetinib plus vemurafenib		Vemurafenib
Overall survival
	Value, median (months)	22.3		17.4
	HRb	0.70c		N/Ad
Progression-free survival
	Value, median (months)	12.3		7.2
	HR	0.58c		N/A
Adverse events (all grade), %			99.2		98
Adverse events (grade ≥3), %			75.3		61.4
Dermatologic adverse events
	Rash (all grade), %	72.5		67.5
	Rash (grade ≥3), %	17		16.3
	Photosensitivity (all grade), %	47.8		37.8
	Photosensitivity (grade ≥3), %	4.5		0
	Alopecia (all grade), %	16.6		30.5
	Alopecia (grade ≥3), %	0.4		0.4
	Hyperkeratosis (all grade), %	10.1		27.2
	Hyperkeratosis (grade ≥3), %	0.4		2.4
	Squamous cell carcinoma (all grade), %	4		12.6
	Squamous cell carcinoma (grade ≥3), %	3.6		12.6
	Keratoacanthoma (all grade), %	1.6		9.3
	Keratoacanthoma (grade ≥3), %	1.2		8.5

^aAdapted from Ascierto et al [13].

^bHR: hazard ratio.

^cCobimetinib plus vemurafenib versus vemurafenib.

^dN/A: not applicable.